Navigation Links
Cempra Expands Clinical Management Team to Advance Leading Antibacterial Clinical Programs Solithromycin and TAKSTA™
Date:3/3/2011

development.  

Jennifer Shranz, M.D., vice president, clinical affairs for Cempra, added, "Our two leading clinical candidates are rapidly progressing to pivotal trials.  In addition, each has several promising applications beyond the lead indications that we are studying presently.  Bringing on these experienced pharmaceutical professionals will help us to both prioritize follow-on indications as well as expertly design all of our clinical development programs."  

About Cempra PharmaceuticalsFounded in 2006, Cempra Pharmaceuticals is a privately-held, clinical-stage pharmaceutical company focused on developing antibacterials to address critical medical needs. Two lead products, both in late-stage clinical trials, address the urgent and increasing need for new treatments targeting drug-resistant bacterial infections in the hospital and in the community. Cempra is well-funded and is committed to developing commercially and medically differentiated and novel products that reduce development risk and provide a high financial return. The company is also utilizing its proprietary compound library and chemistry technology to develop novel macrolides without antibacterial activity for non-antibiotic uses such as COPD, chronic inflammatory and GI disorders. Additional information about Cempra can be found at www.cempra.com.Media Contacts:Russo Partners, LLCRobert E. Flamm, Ph.D.(212) 845-4226 Robert.flamm@russopartnersllc.comTony Russo, Ph.D.(212) 845-4251Tony.russo@russopartnersllc.com
'/>"/>

SOURCE Cempra Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Data Presented on Cempra Pharmaceuticals CEM-101 at the Infectious Diseases Society of America Annual Meeting Reinforces Potency and Coverage Against Multidrug-Resistant S. Pneumoniae Isolates
2. Presentations of Cempra Pharmaceuticals CEM-102 (fusidic acid) at the Infectious Diseases Society of America Annual Meeting Highlight Properties That Make It an Excellent Anti-MRSA Candidate
3. Cempra Pharmaceuticals To Present at the Lazard Capital Markets 6th Annual Healthcare Conference on November 17th
4. Cempra Pharmaceuticals to Present at the Piper Jaffray 21st Annual Health Care Conference
5. Cempra Pharmaceuticals to Present at the UBS Global Life Sciences Conference
6. Cempra Pharmaceuticals Names Richard Kent, M.D., to Its Board of Directors
7. Cempra Pharmaceuticals Names Carl Foster Executive Vice President of Business Development
8. Biodel Inc. Expands Ongoing Phase III VIAject(TM) Clinical Trials Into Europe
9. BiPar Expands Management Team to Advance Lead PARP Inhibitor Product Candidate Into Phase 2 Trials for Cancer
10. Cellectar Expands Clinical Management Team
11. VIA Pharmaceuticals Expands Clinical Trial Program for VIA-2291 in Acute Coronary Syndrome
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... -- CytRx Corporation (Nasdaq: CYTR ), a biopharmaceutical ... that David J. Haen , Vice President, Business ... Biotech Industry Conference on Friday, September 26 th at ... at the Millennium Broadway Hotel in New ... archived webcast of the presentation will be available on ...
(Date:9/18/2014)... , Sept. 18, 2014  Low T Center ... meeting in Hyattsville, Maryland ... assess the proper patient population for testosterone therapy ... risk associated with TRT. Examining recent claims from studies ... that "available epidemiological studies do not provide convincing ...
(Date:9/18/2014)...   MacPractice,s MacPractice MD MU version 5.0 ... which designates that the software is capable of supporting ... 2 Meaningful Use measures required to qualify for funding ... MD MU version 5.0 was certified on June 6, ... the National Coordinator-Authorized Certification Body (ONC-ACB) and is compliant ...
Breaking Medicine Technology:CytRx to Present at BioCentury's 2014 NewsMakers in the Biotech Industry Conference 2CytRx to Present at BioCentury's 2014 NewsMakers in the Biotech Industry Conference 3Low T Center Endorses The Joint FDA Committee Meeting on Testosterone 2MacPractice MD MU Achieves ONC HIT 2014 Edition Complete EHR Certification from ICSA Labs 2MacPractice MD MU Achieves ONC HIT 2014 Edition Complete EHR Certification from ICSA Labs 3MacPractice MD MU Achieves ONC HIT 2014 Edition Complete EHR Certification from ICSA Labs 4MacPractice MD MU Achieves ONC HIT 2014 Edition Complete EHR Certification from ICSA Labs 5
... Sanofi-aventis (EURONEXT: SAN and NYSE: ... today announced that The New England Journal ... II data for the investigational drug iniparib* (BSI-201) ... triple negative breast cancer (mTNBC) when iniparib was ...
... 2011 MiMedx Group, Inc.  (OTC Bulletin ... and marketer of patent protected biomaterial-based products, announced today ... leader in the development of tissue processing techniques for ... amnion membranes. The deal was originally announced on December ...
Cached Medicine Technology:Positive Phase II Results with Iniparib (BSI-201) in Women with Metastatic Triple Negative Breast Cancer Published in The New England Journal of Medicine 2Positive Phase II Results with Iniparib (BSI-201) in Women with Metastatic Triple Negative Breast Cancer Published in The New England Journal of Medicine 3Positive Phase II Results with Iniparib (BSI-201) in Women with Metastatic Triple Negative Breast Cancer Published in The New England Journal of Medicine 4Positive Phase II Results with Iniparib (BSI-201) in Women with Metastatic Triple Negative Breast Cancer Published in The New England Journal of Medicine 5Positive Phase II Results with Iniparib (BSI-201) in Women with Metastatic Triple Negative Breast Cancer Published in The New England Journal of Medicine 6MiMedx Completes Acquisition of Surgical Biologics 2MiMedx Completes Acquisition of Surgical Biologics 3MiMedx Completes Acquisition of Surgical Biologics 4
(Date:9/19/2014)... NY (PRWEB) September 20, 2014 As summer ... Krishnan DMD in Queens, NY now reminds area patients about ... than 80% of our population affected by gum disease, there ... longer.” , For over 20 years Dr. Krishnan has treated ... Hills office location. “Most patients that come in due to ...
(Date:9/19/2014)... collaborative research team led by Medical College of Wisconsin (MCW) ... and insulin levels in rats, mice and in humans. The ... Genetics . , Leah Solberg Woods, Ph.D., associate ... Children,s Hospital of Wisconsin Research Institute, led the study and ... of the paper identified a gene called Tpcn2 in which ...
(Date:9/19/2014)... Albany,NY (PRWEB) September 19, 2014 ... Dr. Reed Ference, is excited to announce the ... with periodontal disease, gingivitis and those needing dental ... the LANAP® laser treatment removes the fear factor ... no stitches, less discomfort and bleeding make, this ...
(Date:9/19/2014)... 2014 York University researchers say a simple ... to detect heightened risk for developing Alzheimer,s disease ... telltale behavioural signs of dementia., Faculty of Health ... who led the study asked the participants to ... on dual screen laptop computers. The test aimed ...
(Date:9/19/2014)... 2014 Recent financial data reveled ... increased their sales by 7% in the last quarter ... industry can be used as a bellwether to determine ... This data has been proven to show trends with ... transportation. Other non-trucking data is largely influenced by international ...
Breaking Medicine News(10 mins):Health News:New York Periodontist Dr. Prabha Krishnan Now Raises Awareness about the Dangers of Untreated Decay, Gingivitis and Gum Disease During Self-Awareness Month 2Health News:New York Periodontist Dr. Prabha Krishnan Now Raises Awareness about the Dangers of Untreated Decay, Gingivitis and Gum Disease During Self-Awareness Month 3Health News:Albany, NY Periodontist Reed Ference, DMD, Calms Fears of Patients with Gum Disease by Offering LANAP®, An Advanced, Less Invasive Treatment Solution 2Health News:Albany, NY Periodontist Reed Ference, DMD, Calms Fears of Patients with Gum Disease by Offering LANAP®, An Advanced, Less Invasive Treatment Solution 3Health News:Simple test can help detect Alzheimer's before dementia signs show: York U study 2Health News:LeaseQ Announces Good News For The Truck Leasing Industry As Truck Rentals In The U.S Continues to Gain Traction 2Health News:LeaseQ Announces Good News For The Truck Leasing Industry As Truck Rentals In The U.S Continues to Gain Traction 3
... , Recent CBO analysis ... 3 A new actuarial analysis by Oliver Wyman, Inc. ... market will be 54 percent higher than they are today ... Protection and Affordable Care Act (PPACA), excluding the impact of ...
... a new factor that is necessary for the development ... of malignant childhood brain cancer. HHMI investigator Huda Y. ... medulloblastoma from developing in mice by shutting down production ... team,s findings, reported in the December 4, 2009, issue ...
... , NEW YORK, Dec. ... H1N1/09 Type A influenza ("Swine Flu") has reached a pandemic ... at least 6,500 fatalities. Since there is no longer ... undoubtedly understate the real situation. , (Photo: ...
... , CHICAGO, Dec. 3 An ... called platelet-rich plasma therapy (PRP), is showing strong potential ... a prominent dental researcher and editor of the ... Rutkowski, DMD, PhD, reported at the recent annual scientific ...
... low number of new cases created by a single ... as vaccination, social distancing and the use of antiviral ... the virus, suggests an epidemiological modelling study http://www.cmaj.ca/cgi/doi/10.1503/cmaj.091807 ... Medical Association Journal ) www.cmaj.ca . ...
... ... specializing in the emerging medical travel space, announced that international medical quality authority, Dr. ... ... 2009 –- Satori World Medical, a leading global healthcare company specializing in the emerging ...
Cached Medicine News:Health News:New Actuarial Analysis Shows Senate Bill Would Significantly Raise Premiums 2Health News:New Actuarial Analysis Shows Senate Bill Would Significantly Raise Premiums 3Health News:New Actuarial Analysis Shows Senate Bill Would Significantly Raise Premiums 4Health News:Researchers identify gene that spurs deadly brain cancer 2Health News:Researchers identify gene that spurs deadly brain cancer 3Health News:Buchang Global Health Forum 2009: An Innovative Approach for Management of H1N1 Swine Flu 2Health News:Platelet-rich Plasma Enhances Bone and Tissue Growth for Dental Implants 2Health News:Vaccination, antivirals and social distancing may blunt impact of H1N1 influenza 2Health News:Former Chief Medical Officer of Joint Commission International Joins Satori World Medical's Medical Quality Advisory Board 2Health News:Former Chief Medical Officer of Joint Commission International Joins Satori World Medical's Medical Quality Advisory Board 3Health News:Former Chief Medical Officer of Joint Commission International Joins Satori World Medical's Medical Quality Advisory Board 4
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: